Novo Nordisk Balances Canadian Price Pressure With Sickle Cell Advance and Oral Pill Triumph
Novo Nordisk rebounds 31% on obesity data, but Canada generic semaglutide threatens pricing. Wegovy oral pill sales surge…
Novo Nordisk’s Sickle Cell Drug Delivers as Buyback Program Advances
Novo Nordisk’s oral sickle cell drug etavopivat met Phase 3 goals, cutting painful crises by 27%. The success…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…